Optimal’s Partners and Senior Attorneys have practiced in the country’s most elite Tech and CPG ecoystems; both within and across from the most well known top-tier law firms.
We left those firms to found Optimal because we saw a gap in the market for lean, elite, scalable legal counsel, without the burdens and dead weight of traditional law firms.
The foundational practice area of Optimal is our expertise in representing venture-backed emerging technology and CPG companies.
With a deep, national client base heavily represented in Austin, Denver, NYC, and California’s thriving CPG ecosystems, Optimal’s Partners are fully versed in the industry norms and expectations for startup and growth-stage CPG companies. Our clients include food and beverage, cannabis, fashion, DTC retail, and supplements.
Sourcing the full spectrum of legal specialties from a single firm is unnecessary, and often counterproductive. Through decades of our lawyers’ collective experience, we’ve curated an elite network of niche-specialty attorneys covering the full spectrum of firm sizes and delivery models. Optimal clients get access to right-sized senior expertise, without the costs of traditional “one stop shop” approaches to full service.
Our Commercial & Tech Transactions lawyers counsel clients on matters including OEM and Reseller Agreements, Licensing and SaaS, University Spin-Outs, TOS and Privacy, Manufacturing and Supply (including Co-Packing), Soft IP, as well as Marketing and Promotion.
We flexibly scale down for lean early-stage companies, but also scale up for larger M&A exits, with top-tier M&A lawyers leading those deals. Optimal clients do not compete for their attorneys’ attention with billion-dollar capital markets transactions. They have direct access to efficient M&A partners who’ve counselled clients on transactions up to 9-figures in exit size.
Life Science and Biotech entrepreneurs face a wide spectrum of legal issues and risks. Optimal’s Partners and Senior Attorneys have decades of cumulative experience advising biotech, pharma, and life science teams from the formation of their companies, through strategic and commercial transactions to high-stakes exits or liquidity transactions.